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Skin Autoﬂuorescence–Indicated Advanced Glycation End Products
as Predictors of Cardiovascular and All-Cause Mortality in High-Risk
Subjects: A Systematic Review and Meta-analysis
Ivan Cavero-Redondo, PhD; Alba Soriano-Cano, MSc; Celia Alvarez-Bueno, PhD; Pedro G. Cunha, PhD; Jose A. Martınez-Hortelano, MSc;
Miriam Garrido-Miguel, MSc; Carlos Berlanga-Macıas, MSc; Vicente Martınez-Vizcaıno, PhD
Background-—Chronic deposits of advanced glycation end products produced by enzymatic glycation have been suggested as
predictors of atherosclerotic-related disorders. This study aimed to estimate the relationship between advanced glycation end
products indicated by skin autoﬂuorescence levels and the risk of cardiovascular and all-cause mortality based on data from
observational studies.
Methods and Results-—We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the
Cochrane Database of Systematic Reviews, and the Web of Science databases from their inceptions until November 2017 for
observational studies addressing the association of advanced glycation end products by skin autoﬂuorescence levels with
cardiovascular and all-cause mortality. The DerSimonian and Laird random-effects method was used to compute pooled
estimates of hazard ratios and their respective 95% conﬁdence intervals for the risk of cardiovascular and all-cause mortality
associated with levels of advanced glycation end products by skin autoﬂuorescence. Ten published studies were included in the
systematic review and meta-analysis. Higher skin autoﬂuorescence levels were signiﬁcantly associated with a higher pooled risk
estimate for cardiovascular mortality (hazard ratio: 2.06; 95% conﬁdence interval, 1.58–2.67), which might not be important to
moderate heterogeneity (I2=34.7%; P=0.163), and for all-cause mortality (hazard ratio: 1.91; 95% conﬁdence interval, 1.42–2.56)
with substantial heterogeneity (I2=60.8%; P=0.0.18).
Conclusions-—Our data suggest that skin autoﬂuorescence levels could be considered predictors of all-cause mortality and
cardiovascular mortality in patients at high and very high risk. ( J Am Heart Assoc. 2018;7:e009833. DOI: 10.1161/JAHA.118.
009833.)
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A dvanced glycation end products (AGEs) are a group ofheterogeneous cross-link formations that result from the
glycation processes involved in several pathologies including
arteriosclerosis and atherosclerosis-related disorders and
particularly complications from micro- and macrovascular
diabetes mellitus.1 Several pathophysiological pathways by
which AGEs contribute to these conditions have been
described, including (1) adduct formations in basement
membranes that permanently change the extracellular matrix
proteins, such as collagen or elastin, and (2) interaction with
AGE receptors, known as receptors for advanced glycation
end products (RAGEs).2 These receptors alter intracellular
signaling cascades and the release of proinﬂammatory
cytokines and, consequently, stimulate oxidative stress in
various cells, such as certain neurons and endothelial or
smooth muscle cells; all these alterations contribute to the
pathological modiﬁcations involved in the start of vascular
complications.3
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From the time of onset of diabetes mellitus, and also for
patients with impaired glucose tolerance, high glucose levels
are present not only in plasma but also within cells (kidney
and retina) and interstitial spaces where the metabolism of
glucose is not insulin dependent.4,5 These elevated glycemic
levels result in increased production of AGEs, fostering the
development of the vascular complications of diabetes
mellitus and chronic kidney disease.6
Conﬂicting results have been reported frommeasurement of
AGE levels in plasma and concern the ability of AGEs to predict
cardiovascular events or cardiovascular mortality, even though
most recent works support such a predictive role.7 Changes in
levels of plasma RAGEs have also been associated indirectly
with increased risk of cardiovascular disease (CVD),8 namely,
heart failure9 and coronary heart disease.10
Although the reference standard for measuring AGE levels
in tissues is biochemical determination in skin biopsies, skin
autoﬂuorescence (SAF) has emerged as a noninvasive,
accurate, and practical method for the analysis of AGE levels
in skin.11,12 SAF-indicated AGE levels are elevated in diabetes
mellitus and end stage renal disease, and some studies
suggest that they are associated with CVD independent of
known CVD risk factors.13–15 In fact, recent reviews have
pointed out a role for SAF levels as new biomarkers of CVD
and diabetes mellitus complications.16,17
To our knowledge, relatively limited evidence exists on the
association of AGE levels measured by SAF with cardiovas-
cular and all-cause mortality, and no meta-analysis has
synthesized this relationship. This systematic review and
meta-analysis aims to estimate the relationship between SAF
levels and the risk of cardiovascular and all-cause mortality
based on data from observational studies.
Methods
This study was performed using available data from published
literature. The data, analytic methods, and study materials are
all available on request by other researchers who want to
reproduce the results or replicate the procedures.
This study was reported according to the MOOSE (Meta-
analysis of Observational Studies in Epidemiology)
statements18 and followed the recommendations of the
Cochrane Collaboration Handbook.19 This systematic review
and meta-analysis was registered through the International
Prospective Register of Systematic Reviews (registration no.
CRD42017058432).
Search Strategy
We systematically searched Medline (via PubMed), Embase,
the Cochrane Central Register of Controlled Trials, the
Cochrane Database of Systematic Reviews, and the Web of
Science databases from their inceptions until November
2017. Observational studies addressing the association of
SAF levels with cardiovascular and all-cause mortality were
eligible. The search expressions are presented in Table S1.
The literature search was complemented by screening of
references included in the articles that were considered
eligible for the systematic review.
Study Selection
Inclusion criteria were as follows: (1) Participants were adults
with diabetes mellitus and/or cardiovascular and/or renal
disease, (2) study design was longitudinal with prospective
data collection, (3) exposure was SAF, and (4) outcome was
cardiovascular or/and all-cause mortality. The criteria for
excluding studies were as follows: (1) Reports were not
written in English or Spanish; (2) studies included individuals
aged <18 years; and (3) publication types were not eligible,
such as review articles, editorials, comments, guidelines, or
case reports.
When >1 study provided data from the same sample, we
considered only the one presenting the most detailed results
or providing data for the largest sample size; however, data
regarding sample characteristics could be extracted from
multiple reports to obtain the most complete information.
The literature search was performed independently by 2
reviewers (I.C.-R. and C.A.-B.), and disagreements were solved
by consensus or by involving a third researcher (V.M.-V.).
Data Extraction and Quality Assessment
The following data were extracted from the original reports:
(1) year of publication, (2) study characteristics (country and
Clinical Perspective
What Is New?
• This systematic review and meta-analysis synthesizes the
evidence supporting higher levels of skin autoﬂuorescence
indicating advanced glycation end products as a predictor of
cardiovascular and all-cause mortality.
• Our data conﬁrm that chronic deposits of skin autoﬂuores-
cence–indicated advanced glycation end products produced
by enzymatic glycation in skin are predictors of cardiovas-
cular and all-cause mortality in patients with diabetes
mellitus and cardiovascular and/or renal diseases.
What Are the Clinical Implications?
• Our ﬁndings highlight that skin autoﬂuorescence levels may
be useful as a biomarker of the risk of mortality assessment
in patients with diabetes mellitus and cardiovascular and
renal diseases.
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length of follow-up), (3) sample characteristics (type of
population; sample size; male sex percentage; age and body
mass index distribution; current smoker status percentage;
and prevalence of diabetes mellitus, hypertension, and
preexisting CVD), (4) SAF levels as the predictor variable,
and (5) cardiovascular or all-cause mortality as the outcome
variable. In addition, the following covariates included in the
studies were extracted: levels of high-sensitivity C-reactive
protein (hs-CRP), systolic and diastolic blood pressure,
hemoglobin, HbA1c, albumin, creatinine, total cholesterol,
LDL (low-density lipoprotein), and triglycerides.
The Quality in Prognosis Studies (QUIPS) tool20 was used
to evaluate the risk of bias in 6 domains: study participation
(sampling bias), study attrition (attrition bias), prognostic
factor measurement, outcome measurement (ascertainment
bias), study confounding, and statistical analysis and report-
ing. Studies were considered to have low risk of bias if they
satisﬁed 5 or all 6 domains, moderate risk of bias if
they satisﬁed 3 or 4 of the 6 domains, or high risk of bias if
they satisﬁed 1 or 2 of the 6 domains.
Data extraction and quality assessment were indepen-
dently performed by 2 researchers (I.C.-R. and C.A.-B.), and
inconsistencies were resolved by consensus or by involving a
third researcher (V.M.-V.).
Statistical Analysis
The DerSimonian and Laird random-effects21 method was
used to compute pooled estimates of hazard ratios (HRs) and
respective 95% conﬁdence intervals (95% CIs) for the risk of
cardiovascular and all-cause mortality associated with SAF
levels. The lowest SAF levels measured as continuous or
categorical variables reported from included studies were
considered as the reference level to calculate pooled HR
estimates. The heterogeneity of results across studies was
evaluated using the I2 statistic and was categorized as might
not be important (0–40%), may represent moderate (30–60%),
may represent substantial (50–90%), and considerable
(75–100%) heterogeneity.18 In addition, the corresponding
P values were considered.
When a study reported several statistical models, only the
one including the largest number of additional covariates was
considered. For each HR estimate, the lnHR was calculated by
converting it to the natural log scale.
Sensitivity analyses (systematic reanalysis while removing
studies one at a time) were conducted to assess the
robustness of the summary estimates. Results of the
sensitivity analyses were considered meaningful when
the resulting estimates were modiﬁed beyond the CIs of the
original summary estimate. In addition, sensitivity analyses
provided insight into whether any particular study accounted
for a large proportion of heterogeneity among the correlation
pooled estimations, based on the change in I2 values (and
associated categories reported previously).
Subgroup analyses were performed based on the type of
target population used to estimate the risk of mortality
associated with SAF levels (diabetes mellitus, cardiovascular,
or renal patients). In addition, subgroup analyses were
performed based on whether or not patients received
hemodialysis. For subgroup analyses, at least 3 studies in
each group were needed.
Random-effects metaregression was used to evaluate
whether results differed according to the length of follow-
up; percentage of male participants; mean age of participants;
prevalence of diabetes mellitus; body mass index; percentage
of current smokers; prevalence of hypertension and preexist-
ing CVD; and levels of baseline SAF, hs-CRP, systolic and
diastolic blood pressure, hemoglobin, HbA1c, albumin, crea-
tinine, total cholesterol, LDL and triglycerides, as these could
be considered major sources of heterogeneity.22
Finally, publication bias was evaluated through visual
inspection of funnel plots and by using the method proposed
by Egger.23 The trim-and-ﬁll computation was used to assess
the effect of publication bias on the interpretation of results.24
Statistical analyses were performed using StataSE software
v14 (StataCorp).
Results
Systematic Review
Of the 56 full-text articles reviewed, only 10 studies25–34 met
the eligibility criteria (Figure 1). Seven studies25,27,28,30.31,33,34
quantiﬁed the risk for all-cause mortality, and 8 samples from 7
studies25–27,29,32,34 quantiﬁed the risk for cardiovascular
mortality. The studies were conducted in 4 European
countries25–28,30–34 and 1 Asian country.29 The reports were
published between 2005 and 2015 (Table 1).
The age of the included participants ranged between 45.0
and 67.5 years, with sample sizes ranging from 48 to 1707
participants. The studies included patients with renal
disease,25,27–29,31,33,34 peripheral artery disease,26 and dia-
betes mellitus.30,32 The percentage of male participants
ranged from 39.3% to 73.0%, and the percentage of current
smokers ranged from 10.0% to 50.0%. Most studies included
a normal weight population,25,28,29,31,32 and only 3 included
an overweight population.26,27,31 The prevalence of hyperten-
sion ranged from 18.0% to 91.0%, and the prevalence of
preexisting CVD ranged from 29.0% to 50.0%.
Studies that included patients with diseases other than
diabetes mellitus (ie, focused on renal and peripheral arterial
disease patients) showed a prevalence of diabetes mellitus
that ranged from 16.6% to 41.9%. Only 2 studies focused on
patients with diabetes mellitus speciﬁed the type of diabetes
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mellitus.30,32 On baseline measurements, SAF levels ranged
from 1.6 to 3.6 arbitrary units.32,34 All studies estimated SAF
using an AGE Reader device (DiagnOptics). The biochemical
(hs-CRP, hemoglobin, HbA1c, albumin, creatinine, total
cholesterol, LDL, and triglycerides) and vascular (systolic
and diastolic blood pressure) covariates of the included
studies are shown in Table 2. Most studies reported models
adjusted for several covariates (Table S2).
Study Quality
As assessed by the QUIPS tool (Table S3), 70% of the studies
had a low risk of bias and 30% had a high risk of bias. The
study attrition domain showed a high risk of bias in 90% of the
studies. Conversely, 100% of the studies showed a low risk of
bias in the statistical analysis and reporting domain, and no
study scored a high risk of bias in the study participation,
statistical analysis and reporting, and study confounding
domains.
Meta-analyses
Higher SAF levels were signiﬁcantly associated with higher
pooled risk estimates for cardiovascular mortality (HR: 2.06;
95% CI, 1.58–2.67) and all-cause mortality (HR: 1.91; 95% CI,
1.42–2.56). Heterogeneity in the HR estimates was not
Figure 1. Literature search: CONSORT (Consolidated Standards of Reporting Trials) diagram.
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important to moderate for the risk of cardiovascular mortality
(I2=34.7%; P=0.163) and substantial for the risk of all-cause
mortality (I2=60.8%; P=0.0.18; Figure 2).
Sensitivity Analysis
The pooled HR estimate was not signiﬁcantly modiﬁed in
magnitude or direction when individual study data were
removed from the analysis one at a time (eg, HRs of 1.86–
2.08 for cardiovascular mortality and 1.74–2.09 for all-cause
mortality). Heterogeneity was modiﬁed from not important to
moderate after removing data from Meerwaldt et al
(I2=43.5%)32 and Fraser et al (I2=43.6%)27 for cardiovascular
mortality. In addition, heterogeneity was modiﬁed from
substantial to moderate only after removing data from
Siriopol et al (I2=47.0%).34
Subgroup Analysis and Metaregression
When analyses were performed based on the type of target
population, there were only enough studies to perform an
analysis in renal patients. The risk of mortality associated
with higher SAF levels in renal patients was 2.23 (95% CI,
1.31–3.82; I2=54.0%) for cardiovascular mortality and 1.88
(95% CI, 1.34–2.64; I2=65.4%) for all-cause-mortality
(Figure 3).
For hemodialysis treatment status analysis, the risk of
cardiovascular mortality associated with higher SAF levels
was 1.97 (95% CI, 1.11–3.49; I2=62.4%) for hemodialysis
patients and 1.95 (95% CI, 1.56–2.45; I2=0.0%) in non-
hemodialysis patients. Nevertheless, for the risk of all-cause
mortality, there were only enough studies to perform an
analysis in hemodialysis patients (HR: 2.08; 95% CI, 1.41–
3.06; Figure 4).
The random-effects metaregression model showed that no
covariate was related to the pooled HR estimates (Table S4).
For cardiovascular mortality, heterogeneity was modiﬁed from
not important to moderate when metaregression models were
based on levels of albumin (I2=42.6%), total cholesterol
(I2=44.2%), and triglycerides (I2=59.7%) and from not impor-
tant to substantial when models were based on hs-CRP levels
(I2=61.8%). Furthermore, for all-cause mortality, heterogeneity
was modiﬁed from substantial to not important when
metaregression models were based on percentage of male
participants (I2=1.4%), body mass index (I2=21.8%), hyperten-
sion prevalence (I2=0.0%), and levels of hs-CRP (I2=26.7%),
systolic blood pressure (I2=0.0%), albumin (I2=16.8%), and
triglycerides (I2=0.0%). heterogeneity for all-cause mortality
was modiﬁed from substantial to moderate when metare-
gression models were based on length of follow-up
(I2=49.4%), diabetes mellitus prevalence (I2=36.4%), percent-
age of current smokers (I2=38.5%), preexisting CVDTa
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prevalence (I2=38.8%), baseline SAF levels (I2=48.3%), and
creatinine levels (I2=41.4%).
Publication Bias
Evidence of publication bias was found by funnel plot
asymmetry and the Egger test for the cardiovascular mortality
estimate (P=0.056) and for the all-cause mortality estimate
(P=0.007; Figure S1). Moreover, trim-and-ﬁll computation
showed that 3 studies were needed to remove publication
bias from both cardiovascular mortality (P=0.909) and all-
cause mortality (P=0.698; Figure S2).
Discussion
This systematic review and meta-analysis provides a synthesis
of the evidence suggesting that higher SAF levels could be a
predictor of cardiovascular and all-cause mortality. Our data
conﬁrm the association between chronic deposits of AGEs
produced by enzymatic glycation in skin and mortality,
suggesting that SAF may be used as a tissue biomarker of
cardiovascular and all-cause mortality risk in patients with
diabetes mellitus, CVD, and renal disease.
Previous studies in which AGE levels were estimated in
plasma have reported ambiguous results regarding the
association between AGE levels and mortality.35,36 Con-
versely, the results of this meta-analysis show that SAF is
consistently associated with mortality. This may be due to the
levels of AGEs in long-lived proteins placed in skin over time,
which is a chronic indicator of AGE levels,37 whereas in blood
plasma, we can ﬁnd AGEs produced in a short period of time,
which may not be directly related to chronic outcomes.
The crucial role of chronic hyperglycemia in the develop-
ment and progression of atherosclerosis and CVD events in
patients with diabetes mellitus or renal disease is not
debatable.38–40 However, the identiﬁcation of AGEs in the
atherosclerotic plaques of nondiabetic patients with coronary
artery disease have magniﬁed the importance of AGEs and
oxidative stress in accelerating atherosclerosis.41 AGEs from
long-lived proteins such as collagens42 predict future
Figure 2. Forest plot including pooled hazard ratios for cardiovascular and all-cause mortality using skin autoﬂuorescence–indicated advanced
glycation end products as predictors. CI indicates conﬁdence interval; D+L, DerSimonian and Laird; I-V, inverse variance.
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progression of microvascular disease, progression of carotid
intima-media thickness, left ventricular mass, and the severity
of coronary artery calcium.43 Accordingly, the results of our
study demonstrate that levels of SAF are associated with
cardiovascular events and cardiovascular mortality. Moreover,
the homogeneity in the results of the longitudinal studies
included in this meta-analysis argues in favor of the validity of
our ﬁndings.
Three pathophysiological mechanisms are known by which
AGEs may cause cardiovascular events and cardiovascular
mortality: (1) AGEs can affect the physiological properties of
cardiac proteins in the extracellular matrix by creating cross-
links, and excessive cross-linking caused by the accumulation
of AGEs weakens the ﬂexibility of the matrix proteins and
produces stiffness in vascular walls44; (2) they can affect
vascular function by inﬂuencing both endothelial function and
vascular compliance, which occurs because AGEs reduce
nitric oxide vasodilator levels45 and favor the production of a
potent vasoconstrictor, endothelin-146; and (3) they can cause
multiple vascular and myocardial changes through interaction
with RAGEs. RAGEs mediate the induction of ﬁbrosis through
the increase of TGF-b (transforming growth factor b)47 and
inﬂuence calcium metabolism in cardiac myocytes.48 In
addition, RAGE interaction may induce atherosclerosis,
thrombosis, and vasoconstriction.49
Some limitations of this study that could compromise our
results should be stated. First, the reasons for death included
in the deﬁnition of all-cause mortality could vary across the
studies included; therefore, misclassiﬁcation bias could
potentially affect our estimates of the associations between
SAF levels and the risk of mortality. Second, there was
evidence of signiﬁcant publication bias with the Egger test,
and results from studies that are not published could have
modiﬁed the results of our meta-analysis. Traditionally,
Figure 3. Forest plot including the pooled hazard ratios for cardiovascular and all-cause mortality in renal patients using skin autoﬂuorescence–
indicated advanced glycation end products as predictors. CI indicates conﬁdence interval; D+L, DerSimonian and Laird; I-V, inverse variance.
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publication bias is thought of as the editorial tendency to
publish signiﬁcant results to the detriment of research
reporting a nonsigniﬁcant relationship between the variables
being analyzed. Moreover, in this study, we cannot neglect
that SAF measurements have not been included as a
cardiovascular risk factor until recently, and this can be a
source of publication bias publication. To better understand
the effect of publication bias on the interpretation of results,
the trim-and-ﬁll computation was used. Finally, although we
extracted the most fully adjusted risk estimates, our results
might still be threatened by residual confounding. Conversely,
this meta-analysis has several strengths: Two searches were
performed across several electronic databases to ensure that
all suitable studies were identiﬁed. Regarding SAF measure-
ments, all included studies used the same device—the AGE
Reader—to perform measurements.
Conclusions
In summary, our data support that SAF levels could be
considered predictors of all-cause mortality and cardiovascu-
lar mortality in patients at high and very high risk. Although
the appropriate use of our results should be understood in
each particular clinical context, our data suggest that
clinicians should consider the level of SAF when they assess
the risk of cardiovascular and all-cause mortality.
Figure 4. Forest plot including the pooled hazard ratios for cardiovascular and all-cause mortality in hemodialysis and nonhemodialysis
patients using skin autoﬂuorescence–indicated advanced glycation end products as predictors. CI indicates conﬁdence interval;
D+L, DerSimonian and Laird; HR, hazard ratio; I-V, inverse variance.
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Notwithstanding, our data highlighted the need for more
research to establish an optimal level of SAF in different
populations to evaluate the appropriateness of including this
biomarker as a routine assessment for cardiovascular risk in
the usual clinical practice of patients at different CVD risk
levels.
Future Perspectives
It would be of particular interest to study the clinical
performance of SAF for predicting cardiovascular events and
mortality risk in patients at moderate risk and in the general
population. Furthermore, it would be important to understand
the increased value of using SAF levels as predictors of CVD
above and beyond the risk estimates that are already in use in
clinical practice.50–53 The deﬁnitive establishment of SAF as a
biomarker of CVD and mortality will be well established once
all the conventional consensus criteria are fulﬁlled.54,55
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Table S1. Search strategy for MEDLINE. 
“Skin 
Autofluorescence" 
OR 
Fluorescence 
OR 
Autofluorescence 
OR 
SAF 
AND 
"Tissue advanced glycation 
end products" 
OR 
"Advanced Glycosylation End 
Products" 
OR 
"Advanced Glycation End 
Products" 
AND 
Cardiovascular 
OR 
Mortality 
OR 
"all-cause mortality" 
OR 
"cardiovascular 
mortality" 
OR 
"cause-specific 
mortality" 
OR 
Death 
OR 
"cardiovascular death" 
OR 
"overall mortality" 
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Table S2. Covariates used for adjusting the data reported by the included studies.   
Reference  Covariates  
Arsov et al 20131 Age, sex, pre-CVD, diabetes mellitus, hypertension, HbSAg, dyalisis duration, 
hs-CRP, ICAM-1, SOD, MPO, albumin.? 
de Vos et al 20142 Age, sex, current smoking, weight status, diabetes mellitus, hypertension, 
lipid-lowering drugs, eGFR, pre-CVD. 
Fraser et al 20143 Age, sex, pre-CVD, diabetes mellitus, hypertension, current smoking, BMI, 
central obesity, total-to-HDL cholesterol ratio, eGFR, uACR, hemoglobin. 
Gerrits et al 20124 Age, albumin, diabetes mellitus, pre-CVD, renal replacement therapy, pulse 
pressure, hematocrit, serum phosphorus, PTH. 
Kimura et al 20145 Age, sex, dyalisis duration, diabetes mellitus, carotid IMT, albumin, 
pentosidine, hs-CRP, pre-CVD. 
Lutgers et al 20086 Sex, pre-CVD. 
Meerwaldt et al 20057 Age, albumin, hs-CRP, diabetes mellitus, dialysis duration, dialysis duration, 
hemodialysis treatment, triglycerides, LDL, smoking, PTH. 
Meerwaldt et al 20078 Age, HbA1c, hypertension, hemodialysis treatment, triglycerides, pre-CVD, 
LDL. 
Nongnuch et al 20159 Sex, Davies’score, dyalisis duration, albumin, cholesterol, phosphate binder, 
ethnicity, pre-CVD, diabetes mellitus, mode of haemodialysis, Kt/v, dialysis 
duration, hs-CRP, urine output, β2 microglobulin. 
Siripol et al 201510 None. 
Pre-CVD: preexisting cardiovascular diseases; HbSAg: hepatitis B surface antigen; hs-
CRP: high-sensitivity C-reactive protein; ICAM-1: Intercellular Adhesion Molecule 1; 
SOD: superoxide dismutase; MPO: Myeloperoxidase; eGFR: estimated glomerular 
filtration rate; HDL: high density lipoprotein; uACR: albumin-to-creatinine ratio; PTH: 
parathyroid hormone; IMT: intima-media thickness; LDL: low density lipoprotein; 
HbA1c: glycated haemoglobin. 
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Table S3. Study quality assessed by QUIPS tool. 
Reference 
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Arsov et al 20131 
de Vos et al 20142 
Fraser et al 20143 
Gerrits et al 20124 
Kimura et al 20145 
Lutgers et al 20086 
Meerwaldt et al 20057 
Meerwaldt et al 20078 
Nongnuch et al 20159 
Siripol et al 201510 
   
: Low risk of bias : Moderate risk of bias : High risk of bias 
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Table S4. Random effect metaregression model. 
 
 Cardiovascular mortality  All-cause mortality 
Covariate Number of studies ? (SE) p I2  Number of studies ? (SE) p I2 
Length of follow up (years) 8 0.18 (0.17) 0.340 14.0  7 -0.01 (0.32) 0.985 49.4 
Male sex (%) 8 0.00 (0.02) 0.998 27.0  7 0.03 (0.01) 0.068 1.4 
Age (years) 8 -0.01 (0.02) 0.679 23.4  7 -0.02 (0.05) 0.730 52.4 
Diabetes mellitus (%) 8 0.01 (0.01) 0.136 0.0  7 0.01 (0.01) 0.284 36.4 
BMI (kg/cm2) 7 -0.10 (0.10) 0.383 3.0  5 -0.14 (0.12) 0.307 21.8 
Current smoker (%) 7 -0.00 (0.01) 0.813 27.4  6 0.04 (0.03) 0.273 38.5 
Hypertension (%) 6 -0.01 (0.01) 0.160 0.0  5 -0.02 (0.01) 0.104 0.0 
Pre-CVD (%) 6 -0.02 (0.03) 0.553 6.0  6 0.01 (0.03) 0.699 38.8 
Baseline SAFs (AU) 8 -0.20 (0.38) 0.619 22.8  7 -0.47 (0.77) 0.567 48.3 
hs-CRP (mg/L) 3 0.04 (0.25) 0.885 61.8  4 0.14 (0.09) 0.270 26.7 
SBP (mmHg) 3 -0.07 (0.08) 0.544 0.0  3 0.06 (0.03) 0.335 0.0 
DBP (mmHg) 3 0.02 (0.04) 0.676 0.0  3 0.01 (0.06) 0.827 69.2 
Haemoglobin (g/dL) 4 0.02 (0.42) 0.960 20.9  4 -0.10 (0.36) 0.805 58.7 
HbA1c (%) 3 0.50 (0.39) 0.419 0.0  N/O - - - 
Albumin (g/L) 3 -0.08 (0.17) 0.720 42.6  4 -0.10 (0.08) 0.322 16.8 
Creatinine (mg/dL) 4 -0.08 (0.09) 0.454 31.1  3 0.02 (0.15) 0.899 41.4 
Total cholesterol (mg/dL) 5 0.01 (0.01) 0.532 44.2  5 0.00 (0.02) 0.875 59.5 
LDL cholesterol (mg/dL) 3 -0.04 (0.05) 0.537 7.0  N/O - - - 
Triglycerides (mg/dL) 4 -0.02 (0.04) 0.640 59.7  3 0.03 (0.13) 0.285 0.0 
SE: standard error; BMI: body mass index; Pre-CVD: preexisting cardiovascular disease; AGEs: advanced glycation end products; AU: arbitrary units; hs-CRP: 
high-sensitivity C-reactive protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated haemoglobin A1c; LDL: low density 
lipoprotein; N/O: not enough observations. 
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Figure S1. Assessment of potential publication bias by Egger test. 
 
A Cardiovascular mortality (p = 0.072) 
 
 
B All-cause mortality (p = 0.007) 
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Figure S2. Assessment of potential publication bias by Egger test post Trim and 
fill. 
A Cardiovascular mortality (p = 0.96) 
 
B All-cause mortality (p = 0.698) 
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